Prescription Medicines
Cefaclin SR Tab.
- Product Category
- Second generation cephalosporin antibiotics
- Active Ingredients
- cefaclor hydrate
- Appearance
- Blue, rectangular, extended-release tablets
- Reimbursement Code
- 648101050
01 / 02
1. Composition and Strength
1 tablet
- Active ingredient: Cefaclor hydrate (KP) ----- 375mg (potency)
- Additives (tar color aluminum lake): Red No. 40, Blue No. 1, Blue No. 2
- Other additives: Stearic acid, magnesium stearate, Opadry 85F40544, hydroxypropyl cellulose, hypromellose 2910, hypromellose phthalate 200731, D-mannitol
2. Effectiveness
- Recurrence of acute bronchitis and chronic bronchitis: Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing bacteria), Haemophilus parainfluenza, Moraxella catarrhalis (including beta-lactamase-producing bacteria), Staphylococcus aureus
- Pharyngitis and tonsillitis: Streptococcus pyogenes (Group A-beta-hemolytic)
- Simple infections of the lower urinary tract (including cystitis and asymptomatic bacteriuria): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus saprophyticus
- Skin and soft tissue infections: Streptococcus pyogenes (Group A-beta-hemolytic), Staphylococcus aureus (including beta-lactamase-producing bacteria), Staphylococcus epidermidis (including beta-lactamase-producing bacteria)
3. Dosage and dosage
As a cefaclor, administer orally twice a day, 375 mg (potency) once.
To treat infections caused by Streptococcus pyogenes (Group A-beta-hemolytic), this drug should be administered continuously for more than 10 days.
Tablets should be taken whole and should not be crushed, ground or chewed.
Increase or decrease appropriately depending on age and symptoms.
This drug is administered orally regardless of meals. However, absorption increases when taken with food.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of shock caused by this drug
2) Patients with a history of hypersensitivity to this drug or cephalosporin antibiotics
2. Administer with caution to the following patients.
1) Patients with a history of hypersensitivity to penicillin antibiotics
2) Patients whose parents or siblings are prone to allergic symptoms such as bronchial asthma, rash, and hives
3) Patients with severe renal impairment
4) Patients with poor oral intake or parenteral nutrition, the elderly, or patients in poor general condition (symptoms of vitamin K deficiency may appear, so observe sufficiently).
5) Patients with a history of gastrointestinal diseases (especially colitis)
3. Adverse reactions
1) Shock: Shock may occur in rare cases, so observe thoroughly and if symptoms appear, stop administration and take appropriate measures.
2) Hypersensitivity reaction: Anaphylactoid symptoms (systemic flushing, edema, difficulty breathing, angioedema, paresthesia, syncope, hypertension, vasodilatation), rash, hives, erythema, itching, fever, lymph node swelling, arthralgia, serum paralysis reaction (with or without rash, erythema multiforme, arthritis, arthralgia, fever) may occur. These symptoms and signs may appear within a few days after starting administration and end administration. It disappears within a few days. Antihistamines and corticosteroids help with recovery.
3) Skin: Stevens-Johnson syndrome and toxic epidermal necrolysis may occur, so observe thoroughly. If these symptoms appear, stop administration and take appropriate measures.
4) Blood system: Occasionally, agranulocytosis, decreased granulocytes, and rarely, decreased pancytosis, anemia, decreased platelets, increased eosinophils, increased lymphocytes, decreased leukocytes, aplastic anemia, hemolytic anemia, and reversible neutrophil decrease may occur. Therefore, sufficiently observe and take appropriate measures, such as discontinuing administration if abnormalities are recognized.
5) Liver: In rare cases, temporary hepatitis, jaundice, and sometimes elevation of AST, ALT, and ALP may occur, so observe thoroughly and discontinue administration if abnormalities appear.
6) Kidney: Severe renal disorders such as reversible interstitial nephritis, rare cases of elevated BUN, elevated serum creatinine, and acute renal failure may occur. Therefore, sufficiently observe the drug by conducting regular tests. If abnormalities are recognized, discontinue administration and take appropriate measures. Some cephalosporin antibiotics may cause seizures when administered without dose reduction, especially to patients with renal impairment. If seizures are related to drug treatment, drug treatment should be discontinued and anticonvulsants administered if clinically necessary.
7) Digestive system: In rare cases, severe colitis accompanied by bloody stool, such as pseudomembranous colitis, may occur. If abdominal pain or frequent diarrhea occurs, take appropriate measures, such as immediately discontinuing administration. Additionally, nausea, vomiting, diarrhea, abdominal pain, stomach discomfort, heartburn, and loss of appetite may sometimes occur.
8) Respiratory system: When administering other Cefem antibiotics, in rare cases, fever, cough, difficulty breathing, abnormal chest
9) Central nervous system: In rare cases, reversible hyperactivity, nervousness, anxiety, hypertonia, nervousness, insomnia, confusion, dizziness, hallucinations, drowsiness, etc. may occur.
10) Mycosis: In rare cases, stomatitis and candidiasis may occur.
11) Vitamin deficiency: In rare cases, symptoms of vitamin K deficiency (hypoprothrombinemia, bleeding tendency, etc.) and vitamin B deficiency symptoms (glossitis, stomatitis, loss of appetite, neuritis, etc.) may appear.
12) Others: In rare cases, headache, genital itching, vaginitis, vaginal moniliasis, etc. may occur.
13) Additional adverse reactions as a result of clinical trials of extended-release tablets are as follows.
Unexpected injury, loss of appetite, anxiety, joint pain, asthma, bronchitis, chest pain, chills, congestive heart failure, conjunctivitis, constipation, dizziness, menstrual pain, indigestion, dysuria, ear pain, edema, fever, abdominal distension, gastritis, infection, insomnia, vaginal discharge, rash, malaise, menstrual irregularity, muscle pain, nausea, vomiting, sore throat, nervousness, enuresis, Otitis media, pain, palpitations, difficulty breathing, sinusitis, drowsiness, sweating, tremors, hives
4. General precautions
1) When using this drug, in order to prevent the development of resistant bacteria, it is advisable to confirm sensitivity and administer only the minimum period necessary for treatment.
2) Interview sufficiently to predict reactions such as shock.
3) As with other antibiotics, the possibility of superinfection by microorganisms resistant to this drug must be considered, and in this case, an appropriate treatment must be selected.
5. Interaction
1) When co-administered with probenecid, the renal excretion rate of this drug is reduced, which may lead to sustained blood concentration.
2) If antacids containing magnesium hydroxide or alumina trihydrate are taken within 1 hour of antibiotic administration, the absorption of this drug is reduced. H2 inhibitors do not affect the rate or amount of absorption of this drug.
3) When administered concurrently with nephrotoxic antibiotics or diuretics (furosemide, ethacrynic acid), renal impairment may increase, so administer with caution.
4) Changes in INR (international normalized ratio): An increase in anticoagulant activity has been reported in patients receiving antibiotics, including this drug, simultaneously with anticoagulants. Infectious diseases (and accompanying inflammatory processes), age and general condition of the patient are risk factors. Although the interaction between this drug and warfarin has not been revealed through clinical trials, INR monitoring should be performed and, if necessary, the dose of oral anticoagulant should be adjusted appropriately. It is more severe for some classes of antibiotics, especially fluoroquinolones, macrolides, cyclins, cotrimoxazole and some cephalosporins.
5) When administered in combination with oral contraceptives, the effectiveness of contraception may be reduced, so it is advisable to additionally use another method of contraception.
6) When administered in combination with bacteriostatic antibiotics (chloramphenicol, erythromycin, tetracycline, etc.), the bactericidal effect of this drug may be reduced.
6. Administration to pregnant and lactating women
1) Since the safety of administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the benefits of treatment are judged to outweigh the risks.
2) It has been reported that a small amount passes into breast milk, so administer with caution to nursing mothers. Small amounts of cefaclor were found in breast milk following a single 500 mg dose. The average concentration in blood was 0.18, 0.20, and 0.16 mg/L after 2, 3, and 5 hours, respectively, and became a trace amount after 1 hour. The effect of this drug on lactation is unknown, so breastfeeding women should use this drug with caution.
7. Administration to children
1) Efficacy and tolerability have not been established in children.
8. Administration to elderly people
When administering to the elderly, keep in mind the following points and administer carefully while observing the patient's condition, paying attention to the dosage and administration interval.
1) Because physiological function is reduced, adverse reactions are likely to occur.
2) Vitamin K deficiency can also cause bleeding.
9. Effect on clinical test values
1) Be careful because false positive results may appear in urine glucose tests using Benedict's reagent, Felling's reagent, or Clini test, excluding test tape reactions.
2) Be careful because a direct Coombs test may result.
10. Treatment in case of overdose
1) Symptoms: Nausea, vomiting, epigastric discomfort, and diarrhea may occur. The degree of epigastric discomfort and diarrhea is related to the dose. When five times the normal dose is administered, gastrointestinal cleansing and medicinal charcoal administration are necessary, and the airway must be protected at this time. Other symptoms may be due to a pre-existing condition, allergic reaction, or the effects of other toxins.
2) Treatment: When treating overdose, overdose of multiple drugs, drug interactions, and abnormal pharmacokinetics must be taken into consideration. An appropriate airway must be secured to enable the patient to breathe, and the patient's physical symptoms, blood gases, and serum electrolytes must be monitored. Drug absorption into the gastrointestinal tract is reduced by administering medicinal charcoal, which in many cases has proven to be more effective than vomiting or gastric lavage, so the use of medicinal charcoal in addition to or instead of gastric lavage should be considered. Repeated use of medicinal charcoal may accelerate the elimination of some absorbed drugs. When using gastrointestinal irrigation or medicinal charcoal, the airway must be protected. The significance of forced urination, peritoneal dialysis, or blood perfusion has not been established.
11. Others
This drug binds to certain essential proteins of the cell wall and inhibits cell wall synthesis, thereby acting as a sterilizer.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Validity period
24 months from date of manufacture
1 tablet
- Active ingredient: Cefaclor hydrate (KP) ----- 375mg (potency)
- Additives (tar color aluminum lake): Red No. 40, Blue No. 1, Blue No. 2
- Other additives: Stearic acid, magnesium stearate, Opadry 85F40544, hydroxypropyl cellulose, hypromellose 2910, hypromellose phthalate 200731, D-mannitol
2. Effectiveness
- Recurrence of acute bronchitis and chronic bronchitis: Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing bacteria), Haemophilus parainfluenza, Moraxella catarrhalis (including beta-lactamase-producing bacteria), Staphylococcus aureus
- Pharyngitis and tonsillitis: Streptococcus pyogenes (Group A-beta-hemolytic)
- Simple infections of the lower urinary tract (including cystitis and asymptomatic bacteriuria): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus saprophyticus
- Skin and soft tissue infections: Streptococcus pyogenes (Group A-beta-hemolytic), Staphylococcus aureus (including beta-lactamase-producing bacteria), Staphylococcus epidermidis (including beta-lactamase-producing bacteria)
3. Dosage and dosage
As a cefaclor, administer orally twice a day, 375 mg (potency) once.
To treat infections caused by Streptococcus pyogenes (Group A-beta-hemolytic), this drug should be administered continuously for more than 10 days.
Tablets should be taken whole and should not be crushed, ground or chewed.
Increase or decrease appropriately depending on age and symptoms.
This drug is administered orally regardless of meals. However, absorption increases when taken with food.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of shock caused by this drug
2) Patients with a history of hypersensitivity to this drug or cephalosporin antibiotics
2. Administer with caution to the following patients.
1) Patients with a history of hypersensitivity to penicillin antibiotics
2) Patients whose parents or siblings are prone to allergic symptoms such as bronchial asthma, rash, and hives
3) Patients with severe renal impairment
4) Patients with poor oral intake or parenteral nutrition, the elderly, or patients in poor general condition (symptoms of vitamin K deficiency may appear, so observe sufficiently).
5) Patients with a history of gastrointestinal diseases (especially colitis)
3. Adverse reactions
1) Shock: Shock may occur in rare cases, so observe thoroughly and if symptoms appear, stop administration and take appropriate measures.
2) Hypersensitivity reaction: Anaphylactoid symptoms (systemic flushing, edema, difficulty breathing, angioedema, paresthesia, syncope, hypertension, vasodilatation), rash, hives, erythema, itching, fever, lymph node swelling, arthralgia, serum paralysis reaction (with or without rash, erythema multiforme, arthritis, arthralgia, fever) may occur. These symptoms and signs may appear within a few days after starting administration and end administration. It disappears within a few days. Antihistamines and corticosteroids help with recovery.
3) Skin: Stevens-Johnson syndrome and toxic epidermal necrolysis may occur, so observe thoroughly. If these symptoms appear, stop administration and take appropriate measures.
4) Blood system: Occasionally, agranulocytosis, decreased granulocytes, and rarely, decreased pancytosis, anemia, decreased platelets, increased eosinophils, increased lymphocytes, decreased leukocytes, aplastic anemia, hemolytic anemia, and reversible neutrophil decrease may occur. Therefore, sufficiently observe and take appropriate measures, such as discontinuing administration if abnormalities are recognized.
5) Liver: In rare cases, temporary hepatitis, jaundice, and sometimes elevation of AST, ALT, and ALP may occur, so observe thoroughly and discontinue administration if abnormalities appear.
6) Kidney: Severe renal disorders such as reversible interstitial nephritis, rare cases of elevated BUN, elevated serum creatinine, and acute renal failure may occur. Therefore, sufficiently observe the drug by conducting regular tests. If abnormalities are recognized, discontinue administration and take appropriate measures. Some cephalosporin antibiotics may cause seizures when administered without dose reduction, especially to patients with renal impairment. If seizures are related to drug treatment, drug treatment should be discontinued and anticonvulsants administered if clinically necessary.
7) Digestive system: In rare cases, severe colitis accompanied by bloody stool, such as pseudomembranous colitis, may occur. If abdominal pain or frequent diarrhea occurs, take appropriate measures, such as immediately discontinuing administration. Additionally, nausea, vomiting, diarrhea, abdominal pain, stomach discomfort, heartburn, and loss of appetite may sometimes occur.
8) Respiratory system: When administering other Cefem antibiotics, in rare cases, fever, cough, difficulty breathing, abnormal chest
9) Central nervous system: In rare cases, reversible hyperactivity, nervousness, anxiety, hypertonia, nervousness, insomnia, confusion, dizziness, hallucinations, drowsiness, etc. may occur.
10) Mycosis: In rare cases, stomatitis and candidiasis may occur.
11) Vitamin deficiency: In rare cases, symptoms of vitamin K deficiency (hypoprothrombinemia, bleeding tendency, etc.) and vitamin B deficiency symptoms (glossitis, stomatitis, loss of appetite, neuritis, etc.) may appear.
12) Others: In rare cases, headache, genital itching, vaginitis, vaginal moniliasis, etc. may occur.
13) Additional adverse reactions as a result of clinical trials of extended-release tablets are as follows.
Unexpected injury, loss of appetite, anxiety, joint pain, asthma, bronchitis, chest pain, chills, congestive heart failure, conjunctivitis, constipation, dizziness, menstrual pain, indigestion, dysuria, ear pain, edema, fever, abdominal distension, gastritis, infection, insomnia, vaginal discharge, rash, malaise, menstrual irregularity, muscle pain, nausea, vomiting, sore throat, nervousness, enuresis, Otitis media, pain, palpitations, difficulty breathing, sinusitis, drowsiness, sweating, tremors, hives
4. General precautions
1) When using this drug, in order to prevent the development of resistant bacteria, it is advisable to confirm sensitivity and administer only the minimum period necessary for treatment.
2) Interview sufficiently to predict reactions such as shock.
3) As with other antibiotics, the possibility of superinfection by microorganisms resistant to this drug must be considered, and in this case, an appropriate treatment must be selected.
5. Interaction
1) When co-administered with probenecid, the renal excretion rate of this drug is reduced, which may lead to sustained blood concentration.
2) If antacids containing magnesium hydroxide or alumina trihydrate are taken within 1 hour of antibiotic administration, the absorption of this drug is reduced. H2 inhibitors do not affect the rate or amount of absorption of this drug.
3) When administered concurrently with nephrotoxic antibiotics or diuretics (furosemide, ethacrynic acid), renal impairment may increase, so administer with caution.
4) Changes in INR (international normalized ratio): An increase in anticoagulant activity has been reported in patients receiving antibiotics, including this drug, simultaneously with anticoagulants. Infectious diseases (and accompanying inflammatory processes), age and general condition of the patient are risk factors. Although the interaction between this drug and warfarin has not been revealed through clinical trials, INR monitoring should be performed and, if necessary, the dose of oral anticoagulant should be adjusted appropriately. It is more severe for some classes of antibiotics, especially fluoroquinolones, macrolides, cyclins, cotrimoxazole and some cephalosporins.
5) When administered in combination with oral contraceptives, the effectiveness of contraception may be reduced, so it is advisable to additionally use another method of contraception.
6) When administered in combination with bacteriostatic antibiotics (chloramphenicol, erythromycin, tetracycline, etc.), the bactericidal effect of this drug may be reduced.
6. Administration to pregnant and lactating women
1) Since the safety of administration during pregnancy has not been established, it should be administered to pregnant women or women who may be pregnant only when the benefits of treatment are judged to outweigh the risks.
2) It has been reported that a small amount passes into breast milk, so administer with caution to nursing mothers. Small amounts of cefaclor were found in breast milk following a single 500 mg dose. The average concentration in blood was 0.18, 0.20, and 0.16 mg/L after 2, 3, and 5 hours, respectively, and became a trace amount after 1 hour. The effect of this drug on lactation is unknown, so breastfeeding women should use this drug with caution.
7. Administration to children
1) Efficacy and tolerability have not been established in children.
8. Administration to elderly people
When administering to the elderly, keep in mind the following points and administer carefully while observing the patient's condition, paying attention to the dosage and administration interval.
1) Because physiological function is reduced, adverse reactions are likely to occur.
2) Vitamin K deficiency can also cause bleeding.
9. Effect on clinical test values
1) Be careful because false positive results may appear in urine glucose tests using Benedict's reagent, Felling's reagent, or Clini test, excluding test tape reactions.
2) Be careful because a direct Coombs test may result.
10. Treatment in case of overdose
1) Symptoms: Nausea, vomiting, epigastric discomfort, and diarrhea may occur. The degree of epigastric discomfort and diarrhea is related to the dose. When five times the normal dose is administered, gastrointestinal cleansing and medicinal charcoal administration are necessary, and the airway must be protected at this time. Other symptoms may be due to a pre-existing condition, allergic reaction, or the effects of other toxins.
2) Treatment: When treating overdose, overdose of multiple drugs, drug interactions, and abnormal pharmacokinetics must be taken into consideration. An appropriate airway must be secured to enable the patient to breathe, and the patient's physical symptoms, blood gases, and serum electrolytes must be monitored. Drug absorption into the gastrointestinal tract is reduced by administering medicinal charcoal, which in many cases has proven to be more effective than vomiting or gastric lavage, so the use of medicinal charcoal in addition to or instead of gastric lavage should be considered. Repeated use of medicinal charcoal may accelerate the elimination of some absorbed drugs. When using gastrointestinal irrigation or medicinal charcoal, the airway must be protected. The significance of forced urination, peritoneal dialysis, or blood perfusion has not been established.
11. Others
This drug binds to certain essential proteins of the cell wall and inhibits cell wall synthesis, thereby acting as a sterilizer.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Validity period
24 months from date of manufacture
Product Updates
Total 1items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 1 | Cefaclin SR Tab. | Cephaclean extended-release tablets (effectiveness, dosage, usage instructions... | 2004.12.23 | HWPCephaclean extended-release tablets.hwp |